Therapeutic strategies targeting specific regulatory axes—such as PINK1-Parkin in ALI/ARDS or FUNDC1 in hypoxic fibrosis—show promise in preclinical models, supported by pharmacological agents ranging from natural compounds (melatonin, resveratrol) to TCM formulations. This evidence concerns the gene PINK1 and acute respiratory distress syndrome.